Monthly Scientific Update – November 2022 (A recent study investigated the effects of PD-L1 expression on cancer cells and tumor-infiltrating immune cells in intrahepatic cholangiocarcinoma (CCA))

PD-L1 on Tumor-Infiltrating Immune Cells: A Potential Prognostic Biomarker for Cholangiocarcinoma Kelly Butler, Dr. Reham Abdel-Wahab Patients may develop cancer when some organ cells acquire mutations that allow rapid and uncontrolled cell proliferation. To survive and spread beyond the initial tumor site, cancer cells must stop the body’s immune system from identifying the cells as…

Read More

Monthly Scientific Update – October 2022 (Breath Tests Could Help Diagnose Cholangiocarcinoma: An Innovative Approach to Early Detection)

Kelly Butler, Dr. Reham Abdel-Wahab Cholangiocarcinoma (CCA) is often detected at an advanced stage that is difficult to treat. Early detection is an important area of research, and scientists are working to develop new tools to detect CCA in its early, more treatable stages. A recent paper laid the necessary groundwork for diagnostic breath tests,…

Read More

Monthly Scientific Update – September 2022 (Precision Therapeutics for Intrahepatic Cholangiocarcinoma)

Kelly Butler, Dr. Reham Abdel-Wahab The traditional chemotherapies gemcitabine and cisplatin have several side effects and have been used to treat cholangiocarcinoma for decades. However, the field of precision oncology is rapidly advancing and generating new, more targeted treatment options. Every tumor is unique, and precision oncology examines the specific genetic alterations in a patient’s…

Read More

Monthly Scientific Update – August 2022 (Preclinical Study Finds that Brusatol may Slow Intrahepatic Cholangiocarcinoma Growth)

Kelly Butler, Dr. Reham Abdel-Wahab Brusatol, a traditionally used Chinese herbal medicine, is currently being explored as a potential cancer treatment in preclinical studies. While the research is still in its early stages,  several studies have found promising results in models of multiple cancer types. A recent laboratory study focused specifically on intrahepatic cholangiocarcinoma (ICC)…

Read More

Monthly Scientific Update – July 2022 (Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures)

Kelly Butler, Dr. Reham Abdel-Wahab A recent study in Precision Oncology examined the diverse genetic and molecular profiles of biliary tract cancers (BTCs). With an eye toward therapeutic value, the study aimed to identify characteristics of each BTC subtype that confer responsiveness to targeted therapies and immunotherapies.  The researchers examined a group of 454 BTC…

Read More

Monthly Scientific Update – June 2022 (Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs. Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma)

The role of locoregional therapy in treating intrahepatic cholangiocarcinoma (iCCA) patients is still limited. Therefore, a group of researchers assessed if using a hepatic arterial infusion pump (HAIP) to deliver high-dose chemotherapy directly into the liver is similar to surgical resection. The researchers enrolled 319 patients with multifocal iCCA, including 141 patients in the HAIP…

Read More

Monthly Scientific Update – May 2022 (Ramucirumab)

Recently, a group of researchers designed a phase II, single-arm clinical trial to evaluate the use of Ramucirumab in the treatment of advanced biliary tract cancer patients. Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2). The researchers enrolled patients with ECOG performance status 0-1 who were previously treated with gemcitabine-based…

Read More

Monthly Scientific Update – April 2022 (the impact of Capecitabine (Xeloda) as adjuvant therapy for surgically resected biliary tract cancers)

Recently, a group of medical oncologists assessed the long-term outcome of a randomized phase III BILCAP trial to evaluate the impact of Capecitabine (Xeloda) as adjuvant therapy for surgically resected biliary tract cancers. Between 2006 and 2014, 447 patients with resectable biliary tract cancer were enrolled in this study. After resecting the tumor, patients were randomized into two…

Read More

Monthly Scientific Update – March 2022

Carl Scheitrum spent more than 1,000 volunteer hours in 2021 updating the International Cholangiocarcinoma Patient Registry. Carl’s information technology experience played a crucial role in this project. He helped the CCF team explore the best approaches to make this registry platform more patient-friendly. He also focused on improving the registry output, so researchers can use…

Read More